sample_product1

On-X®

AORTIC HEART VALVE

A Valve for Life.

Product Highlights

  • The only aortic mechanical valve with FDA, Health Canada, and CE Mark approval for Low INR of 1.5 – 2.0.1*
  • Clinically proven to be safer with less anticoagulation resulting in >60% reduction in bleeding and no increase in thromboembolism.1-2*
  • Unique material and design provide optimal hemodynamics compared with other mechanical and bioprosthetic aortic valves at ≥1 year. 1,3-7

 

*Reduce INR after 3 months of standard therapy.1

Product Overview

1
2
3

1. 90° Leaflet Opening

artivion-on-x-heart-valves

On-X Heart Valves

90° leaflet opening organizes flow1, reducing turbulence and thrombogenicity.3
artivion-all-other-bileafelt-valves

All Other Bileaflet Valves

< 90º leaflet opening can lead to turbulent flow.3

2. Pure Pyrolytic Carbon

Designed to reduce thrombogenicity1-2

product_feature_3

Pure Pyrolytic Carbon2

Other Silicon Alloyed Pyrolutic carbon@2x 1

Silicon-Alloyed Pyrolytic Carbon2

3. Complete Annulus Support

Flared inlet organizes flow & prevents pannus1

Complete Annulus Support

Complete Annulus Support

Incomplete Annulus Support (2)

Incomplete Annulus Support

product_feature_1
On-X Aortic Heart Valve Sizer
On-X Call Out

CYLINDRICAL END

For aortic valve sizes 19-25mm, the cylindrical end is used to find the correct fit.

On-X-Call-Out-Replica-End

REPLICA END

For aortic valve sizes 19-25mm, the replica end is used after sizing to ensure the fit of the valve without obstructing the coronary arteries.

US-On-X-AAP-Acessories-2-810x608

Conical End Sizer

For aortic valve sizes 27/29mm and 31/33mm, the conical end sizer is used to find the correct fit and assure intra-annular positioning.

Clinical Evidence

On-X Aortic Heart Valve: 50% Closer to a Normal INR†1

PROACT (Prospective Randomized On-X Anticoagulation Clinical Trial) determined that On-X Aortic Heart Valve patients with an INR of 1.5–2.0 had a >60% reduction in bleeding events and no increase in thromboembolism (TE) compared to patients with an INR of 2.0–3.0.*2 All other mechanical aortic valve anticoagulation should be managed at an INR of 2.0–3.0.3

 

Normal INR is considered 1.0.1

*Reduce INR after 3 months post-operative standard therapy.4

INR-vs-Event-Rate-2

OPTIMAL HEMODYNAMICS

The On-X Aortic Valve provides optimal mean gradients compared with other bileaflet and bioprosthetic aortic valves at ≥1 year.4-9

Mean-Gradients

Product Animation

The animation below demonstrates how the unique material and design features of the On-X Aortic Heart Valve promote laminar blood flow and reduce thrombogenicity.

Additional Resources

Explore additional resources for On-X below. For further information or to contact a sales associate in your area, contact us.

ORDERING INFORMATION

MRI INFORMATION

PATIENT INFORMATION SITE

Product Highlights

  1. On-X Prosthetic Heart Valve Instructions for Use (01012277E).
  2. Puskas J, et. al. (2014). Reduced anticoagulation after mechanical aortic valve replacement: Interim results from the Prospective Randomized On-X® Valve Anticoagulation Clinical Trial randomized Food and Drug Administration investigational device exemption trial. J Thorac Cardiovasc Surg, 147(4), 1201-11.
  3. St. Jude Medical Physician’s Manual Mechanical Heart Valve.
  4. CarboMedics Prosthetic Heart Valve Instructions for Use.
  5. Medtronic Open Pivot Heart Valve Instructions for Use.
  6. Edwards Life Sciences Carpentier-Edwards PERIMOUNT Magna Ease Pericardial Aortic Bioprosthesis Model 3300TFX Instructions for Use.
  7. Medtronic Mosaic Porcine Bioprosthesis with Cinch Advanced Implant System Instructions for Use.

 

Product Overview

  1. On-X Prosthetic Heart Valve Instructions for Use (01012277E).
  2. LaGrange L, et. al. (1969, June 9-13). Compatibility of carbon and blood. Artificial Heart Program Conference, Washington, DC.
  3. Gerdisch M. et al. (2022) The role of mechanical valves in the aortic position in the era of bioprostheses and TAVR: Evidence-based appraisal and focus on the On-X valve. Prog Cardiovasc Dis. 72:31-40. doi: 10.1016/j.pcad.2022.06.001. 

 

Clinical Evidence

  1. World Health Organization (1983). WHO Expert Committee on Biological Standardization. static/file/WHO_TRS_687.pdf. Accessed on 06/29/2016.
  2. Puskas J, et. al. (2014). Reduced anticoagulation after mechanical aortic valve replacement: Interim results from the Prospective Randomized On-X® Valve Anticoagulation Clinical Trial randomized Food and Drug Administration investigational device exemption trial. J Thorac Cardiovasc Surg, 147(4), 1201-11.
  3. Nishimura RA, et. al. (2017) 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 135, e1159–95.
  4. On-X Prosthetic Heart Valve Instructions for Use (01012277E).
  5. St. Jude Medical Physician’s Manual Mechanical Heart Valve.
  6. CarboMedics Prosthetic Heart Valve Instructions for Use.
  7. Medtronic Open Pivot Heart Valve Instructions for Use.
  8. Edwards Life Sciences Carpentier-Edwards PERIMOUNT Magna Ease Pericardial Aortic Bioprosthesis Model 3300TFX Instructions for Use.
  9. Medtronic Mosaic Porcine Bioprosthesis with Cinch Advanced Implant System Instructions for Use.

All products and indications are not available/approved in all markets. All trademarks are owned by Artivion, Inc. or its subsidiaries. On-X Life Technologies, Inc., Jotec GmbH, and Ascyrus Medical GmbH are wholly owned subsidiaries of Artivion, Inc. MLENG1608.000. (2023-04)

On-X Life Technologies, 1300 E Anderson Ln, Austin, TX 78752, US